A new panel of protein biomarkers discovered in cerebrospinal fluid (CSF) offers the potential for earlier and more accurate diagnosis of multiple sclerosis (MS), particularly in cases where traditional diagnostic methods are inconclusive, researchers announced Monday.
The breakthrough, a collaboration between the Max Planck Institute of Biochemistry and the Technical University of Munich, involved analyzing approximately 1,500 proteins simultaneously in CSF samples from 5,000 individuals across a spectrum of neurological disorders. The findings, published in the journal Cell, pinpoint a 22-protein panel that effectively distinguishes MS from other inflammatory brain diseases, according to a statement from the Max Planck Institute.
Currently, diagnosis of MS relies on a combination of clinical assessment, magnetic resonance imaging (MRI), and laboratory tests, including the detection of oligoclonal bands in CSF. However, a significant number of patients present with non-specific neurological symptoms and lack these classical markers, leading to diagnostic delays and uncertainties. The newly identified protein markers address this challenge by providing a more refined diagnostic tool for these difficult cases.
“This is a significant step forward in our ability to diagnose MS with greater confidence, especially in patients who don’t present with the typical biomarkers,” said Bernhard Hemmer, a neurologist at the Technical University Munich, and Christiane Gasperi, an MS research expert at the same institution, in a joint statement. Matthias Mann, a proteomics expert at the Max Planck Institute, also contributed to the research.
The study utilized high-throughput mass spectrometry to quantify proteins in CSF samples. Researchers not only identified the protein panel for improved diagnosis but also found that the CSF proteome at the time of diagnosis can provide insights into the likely course of the disease, including long-term disability, the risk of transitioning from relapsing to progressive MS, and the timeframe for such progression. A targeted mass spectrometry assay, employing isotope-labeled standards, validated the panel’s effectiveness in an independent cohort, paving the way for potential clinical application.
The research extends beyond MS, with the methodology demonstrating potential for identifying biomarkers for other neurological diseases. The team highlighted proteins of therapeutic interest identified through the proteomic analysis, suggesting new avenues for drug development.
The study acknowledges a potential conflict of interest: Matthias Mann holds an indirect investment in Evosep Biosciences. Franz J. Theurl consults for Immunai Inc., Singularity Bio B.V., CytoReason Ltd, and Cellarity, and has ownership interests in Dermagnostix GmbH and Cellarity.
